173 related articles for article (PubMed ID: 26510590)
1. [Molecular genetic mechanisms of drug resistance in prostate cancer].
Krasnov GS; Dmitriev AA; Sadritdinova AF; Volchenko NN; Slavnova EN; Danilova TV; Snezhkina AV; Melnikova NV; Fedorova MS; Lakunina VA; Belova AA; Nyushko KM; Alekseev BY; Kaprin AD; Kudryavtseva AV
Mol Biol (Mosk); 2015; 49(5):716-27. PubMed ID: 26510590
[TBL] [Abstract][Full Text] [Related]
2. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
4. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells.
Kadowaki Y; Chari NS; Teo AE; Hashi A; Spurgers KB; McDonnell TJ
Apoptosis; 2011 Jun; 16(6):627-35. PubMed ID: 21437722
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
Culig Z; Steiner H; Bartsch G; Hobisch A
Endocr Relat Cancer; 2005 Jun; 12(2):229-44. PubMed ID: 15947099
[TBL] [Abstract][Full Text] [Related]
6. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
7. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
8. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor variation affects prostate cancer progression and drug resistance.
McCrea E; Sissung TM; Price DK; Chau CH; Figg WD
Pharmacol Res; 2016 Dec; 114():152-162. PubMed ID: 27725309
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
[TBL] [Abstract][Full Text] [Related]
11. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
[TBL] [Abstract][Full Text] [Related]
12. Scientists hopeful as they uncover molecular clues to prostate cancer.
Vanchieri C
J Natl Cancer Inst; 2005 Feb; 97(3):168-9. PubMed ID: 15687357
[No Abstract] [Full Text] [Related]
13. Role of lncRNAs in prostate cancer development and progression.
Weiss M; Plass C; Gerhauser C
Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
[TBL] [Abstract][Full Text] [Related]
14. Canonical and Noncanonical Androgen Metabolism and Activity.
Storbeck KH; Mostaghel EA
Adv Exp Med Biol; 2019; 1210():239-277. PubMed ID: 31900912
[TBL] [Abstract][Full Text] [Related]
15. [Prostate cancer and apoptosis].
Mayora A; Arvelo F
Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
[TBL] [Abstract][Full Text] [Related]
16. Amplification and co-regulators of androgen receptor gene in prostate cancer.
Golias Ch; Iliadis I; Peschos D; Charalabopoulos K
Exp Oncol; 2009 Mar; 31(1):3-8. PubMed ID: 19300409
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
Cohen MB; Rokhlin OW
J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor plasticity and its implications for prostate cancer therapy.
Snow O; Lallous N; Singh K; Lack N; Rennie P; Cherkasov A
Cancer Treat Rev; 2019 Dec; 81():101871. PubMed ID: 31698174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
